HomeFinTechLeadArt Biotechnologies: Completes US$6M Pre-A Financing

LeadArt Biotechnologies: Completes US$6M Pre-A Financing

Date:

UK Tribunal Rules Visa and Mastercard Interchange Fees Breach Competition Law

Landmark decision finds payment giants’ multilateral interchange fees unlawful,...

UK Tribunal Rules Visa and Mastercard Fees Violate Competition Law

Landmark Decision Could Reshape Payment Processing Landscape Highlights: The UK...

Belgium Prosecutors Investigate Worldline Local Unit for Potential Misconduct

An In-Depth Look into the Probe and Its Implications...

LeadArt Biotechnologies Completes US$6M Pre-A Financing

  • LeadArt Biotechnologies, a Boston, MA and Ningbo, China-based biotechnology company focused on drug discovery by automating chemoproteomics processes, raised US$6M in Pre-A funding
  • The round was led by BlueRun Ventures Aster
  • The company intends to use the funds to advance the development of its automated chemoproteomics platform and the creation of a human target-probe database
  • LeadArtBiotechnologies is accelerating drug discovery by automating chemoproteomics processes and creating a human live-cell target-probe database
  • Its platform integrates biotechnology and automation technologies to discover disease-related targets and chemical probes for traditionally undruggable and unexplored targets.
Exit mobile version